Trial reportIntensive care medicine2023
Prehospital high-dose methylprednisolone in resuscitated out-of-hospital cardiac arrest patients (STEROHCA): a randomized clinical trial.
Trial report in Intensive care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2025: post-resuscitation care.Intensive care medicine · 2025Guideline
- Pooled it
- Effect of prehospital high-dose glucocorticoid on hemodynamics in patients resuscitated from out-of-hospital cardiac arrest: a sub-study of the STEROHCA trial.Critical care (London, England) · 2024Trial
- Dexamethasone Versus Placebo in Comatose Survivors of Out-of-Hospital Cardiac Arrest: Study Protocol for a Multicenter Randomized Comparison Within the Danish Out-of-Hospital Cardiac Arrest Trial (DANOHCA).Acta anaesthesiologica Scandinavica · 2026Article
- Latest in Resuscitation Research: Highlights from the 2025 American Heart Association's Resuscitation Science Symposium.Journal of the American Heart Association · 2026Article
- Vasopressin, steroids, and epinephrine in out-of-hospital cardiac arrest - a protocol for a randomized controlled trial (OHCA REVIVES trial).Resuscitation plus · 2026Article
- Cardiac arrest triggers IL-17-mediated neuroinflammation and astrocyte polarization: insights into pathogenesis and intervention.Journal of neuroinflammation · 2025Article
- Journal Club Article: The STEROHCA trial - Optimizing post resuscitation haemodynamics by prehospital high dose corticosteroids.Resuscitation plus · 2025Article
- Temporal profiling of myocardial inflammation and recovery in a murine model of cardiac arrest and adrenaline exposure.Resuscitation plus · 2025Article
- Innate Immune Response After Cardiac Arrest (INNATUS): A Study Protocol for an Observational Single-Center Pilot Study.Acta anaesthesiologica Scandinavica · 2025Observational
- Rib fractures after chest compressions for cardiac arrest: retrospective analysis of the AfterROSC1 and AfterROSC2 multicenter databases.Resuscitation plus · 2025Article
- Clinical heterogeneity and phenotyping of post cardiac arrest brain injury: one size may not fit all.Intensive care medicine · 2025Review
- Methylprednisolone effects on serum biochemical factors (CRP, PCT, IL-6, TNF-a) in viral pneumonia.Journal of medical biochemistry · 2025Article
- Neutrophil to high-density lipoprotein cholesterol ratio as a potential inflammatory marker for predicting all-cause mortality in out-of-hospital cardiac arrest survivors.Scientific reports · 2025Article
- Metabolic effects of high-dose glucocorticoid following out-of-hospital cardiac arrest.Intensive care medicine experimental · 2025Article
- Early fluid balance and mortality following extracorporeal cardiopulmonary resuscitation: a high volume, single center study.Scandinavian journal of trauma, resuscitation and emergency medicine · 2025Observational
- The Latest in Resuscitation Research: Highlights From the 2023 American Heart Association's Resuscitation Science Symposium.Journal of the American Heart Association · 2025Article
- Balloon occlusion of the aorta during cardiac arrest -a death blow to the intestines?Scandinavian journal of trauma, resuscitation and emergency medicine · 2025Article
- Association of white blood cell count with one-year mortality after cardiac arrest.Resuscitation plus · 2024Article
- Extracerebral multiple organ dysfunction and interactions with brain injury after cardiac arrest.Resuscitation plus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
purposePatients who are successfully resuscitated following out-of-hospital cardiac arrest (OHCA) are still at a high risk of neurological damage and death. Inflammation and brain injury are components of the post-cardiac arrest syndrome, and can be assessed by systemic interleukin 6 (IL-6) and neuron-specific enolase (NSE). Anti-inflammatory treatment with methylprednisolone may dampen inflammation, thereby improving outcome. This study aimed to determine if prehospital high-dose methylprednisolone could reduce IL-6 and NSE in comatose OHCA patients.
methodsThe STEROHCA trial was a randomized, blinded, placebo-controlled, phase II prehospital trial performed at two cardiac arrest centers in Denmark. Resuscitated comatose patients with suspected cardiac etiology were randomly assigned 1:1 to a single intravenous injection of 250 mg methylprednisolone or placebo. The co-primary outcome was reduction of IL-6 and NSE-blood levels measured daily for 72 h from admission. The main secondary outcome was survival at 180 days follow-up.
resultsWe randomized 137 patients to methylprednisolone (n = 68) or placebo (n = 69). We found reduced IL-6 levels (p < 0.0001) in the intervention group, with median (interquartile range, IQR) levels at 24 h of 2.1 pg/ml (1.0; 7.1) and 30.7 pg/ml (14.2; 59) in the placebo group. We observed no difference between groups in NSE levels (p = 0.22), with levels at 48 h of 18.8 ug/L (14.4; 24.6) and 14.8 ug/L (11.2; 19.4) in the intervention and placebo group, respectively. In the intervention group, 51 (75%) patients survived and 44 (64%) in the placebo group.
conclusionPrehospital treatment with high-dose methylprednisolone to resuscitated comatose OHCA patients, resulted in reduced IL-6 levels after 24 h, but did not reduce NSE levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.